Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment

European Psychiatry

Volumn 25, Issue 4, 2010, Pages 220-229

  Lambert, M ^a   De Marinis, T ^b   Pfeil, J ^c   Naber, D ^a   Schreiner, A ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UO Salute Mentale ASL SA/2   (Italy)

^c Estimate Medical Statistics BV   (Netherlands)

^d Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

Functioning; Quality of life; Remission; Risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; OLANZAPINE; RISPERIDONE; ZUCLOPENTHIXOL; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; ANXIETY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ESTONIA; FEMALE; FOLLOW UP; FRANCE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; GENDER BIAS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PORTUGAL; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RELAPSE; REMISSION; SCHIZOPHRENIA; SEX RATIO; SHORT COURSE THERAPY; SLOVENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; DELAYED RELEASE FORMULATION; EUROPE; INJECTION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; ESTONIA; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PORTUGAL; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RECURRENCE; REMISSION INDUCTION; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SLOVENIA; TREATMENT OUTCOME;

EID: 77952423686     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.09.001     Document Type: Article

References (30)

1. Adler D.A., Bungay K.M., Cynn D.J., Kosinski M. Patient-based health status assessments in an outpatient psychiatry setting. Psychiatr Serv 2000, 51:341-348.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
3. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005, 162:441-449.
4. Csernansky J.G., Schuchart E.K. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002, 16:473-484.
5. Dunayevich E., Sethuraman G., Enerson M., Taylor C.C., Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 2006, 86:300-308.
6. Emsley R., Medori R., Koen L., et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008, 28:210-213.
7. Kane J.M. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006, 67(Suppl. 5):9-14.
8. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
9. Kissling W., Heres S., Lloyd K., Sacchetti E., Bouhours P., Medori R., et al. Direct transition to long-acting risperidone--analysis of long-term efficacy. J Psychopharmacol 2005, 19(5 Suppl.):15-21.
10. Kraemer H.C., Noda A., O'Hara R. Categorical versus dimensional approaches to diagnosis: methodological challenges. J Psychiatr Res 2004, 38:17-25.
11. Lambert M., Naber D., Schacht A., Wagner T., Hundemer H.P., Karow A., et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 2008, 118:220-229.
12. Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T., et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006, 67:1690-1697.
13. Lasser R.A., Bossie C.A., Gharabawi G.M., Kane J.M. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005, 77:215-227.
14. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006, 67(Suppl. 5):3-8.
15. Lindemayer J., Khan A., Eerdekens M., van Hove I., Kushner S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007, 17:138-144.
16. Malla A., Payne J. First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr Bull 2005, 31:650-671.
17. Moeller K.E., Shireman T.I., Liskow B.I. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006, 67:1942-1947.
18. Möller H.J., Llorca P.M., Sacchetti E., Martin S.D., Medori R., Parellada E., et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005, 20:121-130.
19. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009; 24:287-96.
20. Patel M.X., Young C., Samele C., Taylor D.M., David A.S. Prognostic indicators for early discontinuation of risperidone long-acting injection. Int Clin Psychopharmacol 2004, 19:233-239.
21. Peralta V., Cuesta M.J. Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach. J Affect Disord 2008, 108:71-86.
22. Petersen L., Thorup A., Øghlenschlaeger J., et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry 2008, 53:660-670.
23. Remington G., Kapur S. Remission: what's in a name?. Am J Psychiatry 2005, 162:2393-2394.
24. Salokangas R.R. Symptom dimensions and outcome in schizophrenia. World Psychiatry 2003, 2:172-178.
25. Schooler N.R. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 2006, 67(Suppl. 5):19-23.
26. Taylor D., Atkinson J., Fischetti C., Sparshatt A., Jones S. A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome. Acta Psychiatr Scand 2007, 116:461-466.
27. Taylor D.M., Fischetti C., Sparshatt A., et al. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2009, 70:196-200.
28. van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006, 113:91-95.
29. Ware J.E., Snow K., Kosinski M., Gamdek B. SF-36 health survey manual and interpretation guide 1997, The Health Institute, New England Medical Center, Boston, MA.
30. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995, 21:419-429.